Table 1.
The clinicopathological characteristics of the patients.
| Age (median, range) | 58 (20–85) years | |
|---|---|---|
| N | % | |
| < 65 years | 219 | 71.6 |
| ≥ 65 years | 87 | 28.4 |
| Gender | ||
| Female | 155 | 50.7 |
| Male | 151 | 49.3 |
| ECOG PS | ||
| 0 | 77 | 25.5 |
| 1 | 158 | 52.5 |
| 2 | 51 | 17 |
| 3 | 15 | 5 |
| Smoking | ||
| No | 175 | 58 |
| ≤ 10 package/year | 36 | 11.9 |
| > 10 package/year | 91 | 30.1 |
| Tumor histology | ||
| Adenocarcinoma | 289 | 94.4 |
| NOS (not other specified) | 11 | 3.6 |
| Squamous cell carcinoma | 5 | 1.6 |
| Mixt (adeno-squamous) | 1 | 0.4 |
| Present driver mutation status | ||
| EGFR | 210 | 68.6 |
| Exon 21 | 61 | 28.8 |
| Exon 19 del | 131 | 61.8 |
| Rare | 20 | 9.4 |
| ALK | 85 | 27.6 |
| ROS1 | 8 | 2.6 |
| BRAF | 2 | 0.6 |
| Number of BM | ||
| 1–3 | 188 | 61.6 |
| ≥ 4 | 117 | 38.4 |
| Extracranial metastases | ||
| Yes | 265 | 86.6 |
| No | 41 | 13.4 |
| Local treatment for BM | ||
| No | 28 | 9.6 |
| Surgery | 28 | 9.6 |
| WBRT | 123 | 42.4 |
| SRS | 98 | 33.8 |
| WBRT plus SRS | 2 | 0.7 |
| Surgery plus SRS | 6 | 2 |
| Surgery plus WBRT | 5 | 1.7 |
| RT after first BM progression | 78 | |
| SRS | 20 | 25.6 |
| WBRT | 30 | 38.5 |
| Follow-up | 28 | 35.9 |
| RT after second BM progression | 32 | |
| SRS | 10 | 31.3 |
| WBRT | 6 | 18.7 |
| Follow-up | 16 | 50 |
| RT after third BM progression | 14 | |
| SRS | 6 | 42.85 |
| WBRT | 1 | 7.15 |
| Follow-up | 7 | 50 |
| 1st line treatment | ||
| Erlotinib | 115 | 37.7 |
| Gefitinib | 19 | 6.2 |
| Afatinib | 27 | 8.9 |
| Osimertinib | 6 | 2 |
| CT | 51 | 16.7 |
| Crizotinib | 25 | 8.2 |
| Alectinib | 51 | 16.7 |
| Brigatinib | 1 | 0.3 |
| Ceritinib | 4 | 1.3 |
| Dacomitinib | 1 | 0.3 |
| Dabrafenib plus trametinib | 1 | 0.3 |
| Other | 4 | 1.3 |
| 2nd line treatment | 118 | |
| Erlotinib | 27 | 22.9 |
| Afatinib | 6 | 5 |
| Osimertinib | 41 | 34.7 |
| CT | 20 | 16.9 |
| Crizotinib | 4 | 3.4 |
| Alectinib | 10 | 8.5 |
| Brigatinib | 2 | 1.7 |
| Lorlatinib | 8 | 2.3 |
| 3rd line treatment | 38 | |
| Erlotinib | 1 | 2.6 |
| Osimertinib | 5 | 13.1 |
| CT | 23 | 60.5 |
| Crizotinib | 1 | 2.6 |
| Alectinib | 2 | 5.2 |
| Brigatinib | 2 | 5.2 |
| Ceritinib | 1 | 2.6 |
| Lorlatinib | 2 | 5.2 |
| Nivolumab | 1 | 2.6 |
| 4th line treatment | 9 | |
| Erlotinib | 2 | 22.2 |
| Afatinib | 1 | 11.1 |
| CT | 4 | 44.5 |
| Alectinib | 2 | 22.2 |
PS performance status, BM brain metastasis, RT radiotherapy, SRS stereotactic radiosurgery, WBRT whole-brain radiotherapy, CT chemotherapy.